Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Feb 3, 2023
- Accession no.
- 0001447362-23-000015
- Filed
- Feb 3, 2023
- Trade date
- Feb 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions. Open-market sales total $227.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Common Stock | SSaleDisposed | −2,795 | $27.11F2 | −$75,772.45 | 168,733 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −1,398 | $27.11F2 | −$37,899.78 | 121,930 | Indirect | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −1,398 | $27.11F2 | −$37,899.78 | 110,825 | Indirect | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −699 | $27.11F2 | −$18,949.89 | 24,399 | Indirect | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −698 | $27.11F2 | −$18,922.78 | 24,401 | Indirect | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −698 | $27.11F2 | −$18,922.78 | 24,401 | Indirect | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −698 | $27.11F2 | −$18,922.78 | 24,393 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $26.830 to $27.555, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.